TITLE

Differential Effects of Pneumococcal Vaccines against Serotypes 6A and 6C

AUTHOR(S)
Park, In H.; Moore, Matthew R.; Treanor, John J.; Pelton, Stephen I.; Pilishvili, Tamara; Beall, Bernard; Shelly, Mark A.; Mahon, Barbara E.; Nahm, Moon H.
PUB. DATE
December 2008
SOURCE
Journal of Infectious Diseases;12/15/2008, Vol. 198 Issue 12, p1818
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Because classic pneumococcal serotyping methods cannot distinguish between serotypes 6A and 6C, the effects of pneumococcal vaccines against serotype 6C are unknown. Pneumococcal vaccines contain serotype 6B but not serotypes 6A and 6C. Methods. We used a phagocytic killing assay to estimate the immunogenicity of the 7-valent conjugate vaccine (PCV7) in children and the 23-valent polysaccharide vaccine (PPV23) in adults against serotypes 6A and 6C. We evaluated trends in invasive pneumococcal disease (IPD) caused by serotypes 6A and 6C in the United States, using active surveillance. Results. Serum specimens from PCV7-immunized children had median opsonization indices of 150 and <20 for serotypes 6A and 6C, respectively. Similarly, only 52% of adults (25 of 48) vaccinated with PPV23 showed opsonic indices of >20 against serotype 6C. During 1999-2006, the incidence of serotype 6A IPD decreased by 91% (from 4.9 to 0.46 cases per 100,000 persons; P < .05) among individuals aged <5 years and by 58% (from 0.86 to 0.36 cases per 100,000 persons; P < .05) among those aged ⩾5 years. Although the incidence of 6C IPD showed no consistent trend (range, 0-0.6 cases per 100,000 persons) among individuals aged <5 years, it increased from 0.25 to 0.62 cases per 100,000 persons (P < .05) among those aged ⩾5 years. Conclusions. PCV7 introduction has led to reductions in serotype 6A IPD but not serotype 6C IPD in the United States.
ACCESSION #
43804680

 

Related Articles

  • Child vaccine delayed by six months.  // Pulse;6/1/2006, Vol. 66 Issue 22, p2 

    The article reports that general practitioner negotiators have warned that pneumococcal vaccination will not be introduced into the childhood schedule in Great Britain until the end of 2006 at the earliest. The warning is confirmation that the vaccine will be delayed from its proposed...

  • Pneumococcal Immunization: From Policy to Practice. Schwartz, Benjamin; Breiman, Robert F. // JAMA: Journal of the American Medical Association;9/5/90, Vol. 264 Issue 9, p1154 

    Editorial. Deals with the low utilization of pneumococcal vaccines targeted for adults in the U.S. Factors behind the lack of use of pneumococcal vaccines; Strategies that can be adopted to increase utilization of pneumococcal vaccines; Cost benefits of immunization.

  • Pneumococcal vaccine gets go-ahead in child schedule. Wilkinson, Emma; Pedder, Cato // Pulse;1/8/2005, Vol. 65 Issue 1, p12 

    Reports on the inclusion of a pneumococcal vaccine to the childhood immunization schedule in Great Britain. Agreement of the Joint Committee on Vaccination and Immunisation on the pneumococcal vaccination; Difficulties in the introduction of the vaccine; Benefits of the vaccine. INSETS: The...

  • Emergence of a Multiresistant Serotype 19A Pneumococcal Strain Not Included in the 7-Valent Conjugate Vaccine as an Otopathogen in Children. Pichichero, Michael E.; Casey, Janet R. // JAMA: Journal of the American Medical Association;10/17/2007, Vol. 298 Issue 15, p1772 

    This article presents a study seeking to address concerns that a multiresistant strain of pneumococcal bacteria has surfaced in the U.S. and is not covered by the 7-valent conjugate vaccine approved by the Food & Drug Administration (FDA). The vaccine had a significant impact on stopping...

  • Are Anticapsular Antibodies the Primary Mechanism of Protection against Invasive Pneumococcal Disease? Lipsitch, Marc; Whitney, Cynthia G.; Zell, Elizabeth; Kaijalainen, Tarja; Dagan, Ron; Malley, Richard // PLoS Medicine;Jan2005, Vol. 2 Issue 1, p62 

    Background Antibody to capsular polysaccharide has been the basis of several vaccines that offer protection against invasive disease from Streptococcus pneumoniae. The success of such vaccines has led to the inference that natural protection against invasive pneumococcal disease is largely...

  • GP Business: Ensuring pneumococcal and flu jabs work for you. Summerton, Nick // GP: General Practitioner;10/1/2004, p49 

    This article states that direct enhanced services (DES) rules encourage good immunization programs. In primary care pneumococcal immunization has always been the poor relation to influenza immunization. Although both flu and pneumococcal diseases are common causes of hospitalization and death in...

  • Use of Pneumococcal Conjugate Vaccine to Decrease Rates of Bacterial Meningitis. Dagan, Ron // Clinical Infectious Diseases;6/1/2008, Vol. 46 Issue 11, p1673 

    The article focuses on the therapeutic use of 7-valent pneumococcal conjugate vaccine (PCV7) to reduce the rates of bacterial meningitis. Study shows that the vaccine reduces pneumococcal infections in adult and pediatric contacts after its introduction. Its effect on the subset of pneumococcal...

  • Nasopharyngeal carriage rate of Streptococcus pneumoniae in Ugandan children with sickle cell disease.  // BMC Research Notes;2012, Vol. 5 Issue 1, p28 

    The article offers information on a study conducted by the authors related to streptococcus pneumoniae (S. pneumoniae) in sickle cell disease patients in Kampala, Uganda. They studied the nasopharyngeal carriage rate of S. pneumoniae in children with homozygous sickle cell disease (HbSS), who...

  • Polysaccharide pneumococcal vaccines. Jefferson, Tom // BMJ: British Medical Journal (International Edition);8/10/2002, Vol. 325 Issue 7359, p292 

    Editorial. Discusses polysaccharide pneumococcal vaccines, which is used to prevent infection with Streptococcus pneumoniae (pneumococcus). Epidemiology of pneumococcal disease; Effectiveness of the vaccines; Possibility that protein conjugate pneumococcal vaccines show clearer effectiveness;...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics